Biora Therapeutics, Inc. (NASDAQ:BIOR) Sees Large Drop in Short Interest

Biora Therapeutics, Inc. (NASDAQ:BIOR) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 140,800 shares, a decrease of 93.4% from the September 30th total of 2,130,000 shares. Approximately 4.1% of the company’s stock are sold short. Based on an average trading volume of 30,500 shares, the days-to-cover ratio is currently 4.6 days.

Biora Therapeutics Stock Up 11.4 %

NASDAQ:BIOR opened at $3.90 on Friday. Biora Therapeutics has a twelve month low of $3.38 and a twelve month high of $21.10. The business has a 50 day moving average price of $5.89 and a two-hundred day moving average price of $6.40. The company has a market cap of $14.35 million, a P/E ratio of -0.07 and a beta of 1.22.

Biora Therapeutics (NASDAQ:BIOR) last released its quarterly earnings data on Monday, August 12th. The company reported ($3.50) EPS for the quarter, beating the consensus estimate of ($4.50) by $1.00. The company had revenue of $0.32 million during the quarter. As a group, analysts anticipate that Biora Therapeutics will post -12.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of Biora Therapeutics in a research report on Tuesday, August 13th.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.